PCSK9 and familial hypercholesterolemia: The gain-of-function mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9)—which binds and targets LDLR for lysosomal degradation—also underlie a subclass of familial hypercholesterolemia.